Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FCRU7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,332
Award facts
- Contract value 100% obligated
- $19,332.22 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) issued a delivery order valued at $19,332.22 to DMS Pharmaceutical Group Inc. on January 12, 2026, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will perform the work at its Park Ridge facility with an ultimate completion date of January 13, 2026. This delivery order was issued under a firm fixed-price contract structure with no set-aside designation, allowing the contractor to compete in unrestricted federal procurement.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the DLA, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The parent IDC, awarded on November 13, 2025, carries a $499.9 billion ceiling value and extends through December 31, 2036, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors within the DLA's broader $30.3 billion PPV-G GEN V pharmaceutical acquisition strategy. The PPV-G GEN V program authorizes the DLA to issue delivery orders for comprehensive pharmaceutical products and medical consumables to support the recurring medical supply needs of Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group has demonstrated substantial federal contracting activity and competitive capability across multiple therapeutic categories, with no identified subcontractors on this award.
Quick answers
Who was awarded contract SPE2DR26FCRU7?
SPE2DR26FCRU7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FCRU7 worth?
The government has obligated $19,332 on SPE2DR26FCRU7.
Is contract SPE2DR26FCRU7 an order under another contract?
Yes. SPE2DR26FCRU7 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRU7 competed?
The extent of competition for SPE2DR26FCRU7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award